ABPI Logo
  • Developing medicines
    • Responding to COVID-19
    • Clinical trials and research
    • Building a thriving environment for medicine discovery
    • UK-EU Future Relationship
    • Life Sciences Industrial Strategy
    • ABPI Medical Representatives Exam
  • Accessing medicines
    • How medicines are priced in the UK
    • Working with the NHS
    • Supply chain
    • Antimicrobial resistance (AMR)
    • Vaccines
    • What is the NICE Methods Review?
    • Rare diseases: Facing three challenges
  • Our ethics
    • ABPI Code of Practice
    • Disclosure UK
    • Appropriate prescribing
    • Patient & public involvement
  • Member representation
    • Events
    • Full membership
    • Working with our members​
    • ABPI Members List
    • Membership benefits
  • Who We Are
  • Media
  • Publications
  • Facts and Figures
  • Contact Us
MY ABPI LOGIN
 
  • The Association of the British Pharmaceutical Industry
  • Media centre
  • Archive
  • News
  • News and Press Releases - 2020

News and Press Releases - 2020

14 Jan 2020 Novartis announces new collaboration for patients

21 Jan 2020 Pharmaceutical companies give NHS Scotland £1 million a week to help fund new treatments

22 Jan 2020 Government launches Statutory Scheme consultation

28 Jan 2020 Immigration reforms must support UK life sciences

03 Feb 2020 ABPI response to proposed UK-EU trade negotiation approaches

05 Feb 2020 New toolkit for Welsh NHS and industry to work together for patients

06 Feb 2020 ABPI response to proposed UK-‘Rest of the World’ FTA negotiation approaches

19 Feb 2020 ABPI response to new UK immigration system

27 Feb 2020 ABPI response to the UK’s approach to EU negotiations

02 Mar 2020 ABPI response to UK negotiating objectives for US FTA

11 Mar 2020 Pharmaceutical industry response to Budget 2020

16 Mar 2020 ABPI update on the pharmaceutical industry's response to coronavirus

19 Mar 2020 Q4 2019 figures for Voluntary Scheme published

01 Apr 2020 Joint statement on COVID-19 testing and diagnostics

08 Apr 2020 ABPI responds to Government’s coronavirus testing ‘call to arms’

23 Apr 2020 Global manufacturing ‘fundamental’ for continued NHS medicine supply

12 May 2020 ABPI response to safer working guidance

21 May 2020 ABPI comment on NIHR framework for restarting paused research

22 May 2020 ABPI response to quarantine measures

28 May 2020 Temporary changes to publication of 2019 data on Disclosure UK in June 2020

04 Jun 2020 Public-private alliance to provide immunisation programs for 300 million children globally

18 Jun 2020 ABPI response to antibiotic development scheme

19 Jun 2020 ABPI consults on new-look Code of Practice

30 Jun 2020 Pharmaceutical industry invests £381 million in UK R&D collaborations - 2019 data on Disclosure UK

01 Jul 2020 ABPI response to Government R&D Roadmap

06 Jul 2020 Supercharging R&D investment critical to boosting British business

08 Jul 2020 ABPI response to Cumberlege Review

08 Jul 2020 Pharmaceutical industry response to Chancellor’s economic statement

09 Jul 2020 $1 billion antibiotics research fund launched by pharmaceutical companies

14 Jul 2020 William Harbage QC to step down as Chair of the PMCPA Appeal Board

20 Jul 2020 Positive results for the Oxford vaccine welcomed by ABPI

29 Jul 2020 ABPI response to Committee inquiry into COVID-19 and international trade

04 Aug 2020 Preparing for the end of Brexit transition: Our response to DHSC guidance

07 Aug 2020 Northern Ireland Protocol: Our response to additional guidance

07 Aug 2020 Northern Ireland Protocol: Our response to additional guidance

18 Aug 2020 ABPI response to new National Institute for Health Protection

01 Sep 2020 ABPI supports AMRC call to protect charity research

01 Sep 2020 ABPI response to MHRA guidance for the end of the transition period

11 Sep 2020 Pharmaceutical industry reaction to UK-Japan trade agreement

28 Sep 2020 COVID threat must inject urgency into trade talks, say UK & EU pharma bodies

28 Sep 2020 ABPI response to UK genomics strategy

29 Sep 2020 ABPI response to NHS Confederation reports: NHS Reset and Health inequalities

30 Sep 2020 Last-ditch attempt to secure ‘bare minimum’ deal on medicines, MPs told

07 Oct 2020 UK leading Europe in clinical trials, but strategy needed to restart non-COVID research

08 Oct 2020 New partnership to reduce disease burden in Northern Ireland - starting with Hepatitis C

13 Oct 2020 ABPI response to Government-secured Brexit freight capacity

14 Oct 2020 ABPI response to UK joining Project Orbis and Access Consortium

16 Oct 2020 ABPI response to human medicines regulations changes

16 Oct 2020 ABPI response to PM's Brexit comments

20 Oct 2020 Northern Ireland life sciences sector ‘flourishing’

06 Nov 2020 ABPI response to consultation on NICE's methods

06 Nov 2020 Joint EU-UK pharmaceutical industry response to Specialised Committee outcome

25 Nov 2020 ABPI response to the Spending Review

27 Nov 2020 Disclosure UK: Further detail for 2019 published

30 Nov 2020 ABPI response to £20 million medicines manufacturing fund

02 Dec 2020 ABPI response to first COVID-19 vaccine approval

 

News

  • News and Press Releases - 2020
  • News and Press Releases - 2019
  • News and Press Releases - 2018

ABPI

The Association of the British Pharmaceutical Industry is a company limited by guarantee registered in England and Wales 
(registered number 09826787) and its registered office is at 7th Floor Southside,105 Victoria Street, London, SW1E 6QT.
Telephone +44 (0) 207 9303477

© ABPI 2021
  • Twitter Logo
  • LinkedIn
  • YouTube Logo

Devolved Nations

  • Cymru Wales
  • Northern Ireland
  • Scotland

Quick Links

  • ABPI Exam
  • Disclosure UK
  • Frequently Asked Questions
  • Careers
  • Schools
  • Acronym buster

Website Info

  • Terms and conditions
  • Accessibility
  • Cookie Policy

Prescription Medicines Code of Practice Authority (PMCPA)

The Prescription Medicines Code of Practice Authority (PMCPA) was established by The Association of the British Pharmaceutical Industry to operate the ABPI Code of Practice for the Pharmaceutical Industry independently of the ABPI. The PMCPA is a division of ABPI which is a company registered in England and Wales (registered number 09826787) with its registered office at 7th Floor, Southside, 105 Victoria Street, London SW1E 6QT.

Office of Health Economics (OHE)

The Office of Health Economics (OHE) is a company limited by guarantee registered in England and Wales (registered number 09848965) and its registered office is at 7th Floor Southside, 105 Victoria Street, London, SW1E 6QT. OHE provides independent research, advisory and consultancy services on policy implications and economic issues within the pharmaceutical, health care and biotechnology sectors.